Cardinal Health raises FY2026 guidance on specialty-drug demand

What happened

Cardinal Health ($CAH) lifted its fiscal 2026 earnings guidance to at least $10.00 per share (up from $9.65–$9.85), signaling stronger momentum than the market expected. Management also pointed to continued growth in specialty medicines (projecting over $50B in specialty revenue) and expansion in services tied to drug development and commercialization.

Why the market cares

1. Specialty drugs are high-complexity, high-dollar, and typically higher-margin to handle and distribute, which can lift distributor profitability even if overall volumes are steady.

2. If a major distributor is raising outlook, it often signals broader strength in the pharma supply chain (pricing, mix, services attach rates).

3. Updates on navigating ...